Your browser doesn't support javascript.
loading
[Clinical use of botulinum toxin type A in pain medicine]. / Klinische Anwendung von Botulinumtoxin Typ A in der Schmerzmedizin.
Schwarzer, A; Mäcken, T; Enax-Krumova, E K.
Afiliação
  • Schwarzer A; Abteilung für Schmerzmedizin, BG Universitätsklinikum Bergmannsheil gGmbH, Ruhr-Universität Bochum, Bürkle-de-la-Camp-Platz 1, 44789, Bochum, Deutschland. andreas.schwarzer@bergmannsheil.de.
  • Mäcken T; Klinik für Anästhesiologie, Intensiv- und Schmerzmedizin, BG Universitätsklinikum Bergmannsheil gGmbH, Ruhr-Universität Bochum, Bochum, Deutschland. andreas.schwarzer@bergmannsheil.de.
  • Enax-Krumova EK; Klinik für Anästhesiologie, Intensiv- und Schmerzmedizin, BG Universitätsklinikum Bergmannsheil gGmbH, Ruhr-Universität Bochum, Bochum, Deutschland.
Schmerz ; 37(4): 297-307, 2023 Aug.
Article em De | MEDLINE | ID: mdl-37365293
ABSTRACT
Botulinum toxin has been used for decades in the treatment of a variety of painful diseases. Botulinum toxin not only blocks neuromuscular transmission, but also the secretion of neuropeptides, such as substance P, glutamate and calcitonin gene-related peptide (CGRP) and thus inhibits neurogenic inflammation. In addition, it has a modulatory pain-relieving effect via retrograde transport into the central nervous system. In addition to approval for the treatment of dystonia or spasticity, onabotulinum toxin A is also approved for the prophylaxis of chronic migraine if the oral prophylactic migraine medication has had an insufficient effect or has not been tolerated. In addition, botulinum toxin is also recommended in guidelines as a third-line treatment for neuropathic pain, but in Germany this is an off-label application. This article provides an overview of the current clinically relevant areas of application of botulinum toxin in the field of pain medicine.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_doencas_nao_transmissiveis Assunto principal: Toxinas Botulínicas Tipo A / Transtornos de Enxaqueca / Fármacos Neuromusculares Tipo de estudo: Guideline Limite: Humans Idioma: De Revista: Schmerz Assunto da revista: NEUROLOGIA Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_doencas_nao_transmissiveis Assunto principal: Toxinas Botulínicas Tipo A / Transtornos de Enxaqueca / Fármacos Neuromusculares Tipo de estudo: Guideline Limite: Humans Idioma: De Revista: Schmerz Assunto da revista: NEUROLOGIA Ano de publicação: 2023 Tipo de documento: Article
...